Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers

Nat Biotechnol. 2012 Oct;30(10):906-7. doi: 10.1038/nbt1012-906c.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing / pharmacology
  • Antibodies, Neutralizing / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic*
  • Humans
  • Immunoglobulins, Intravenous / pharmacology
  • Immunoglobulins, Intravenous / therapeutic use
  • Insulin-Like Growth Factor I / antagonists & inhibitors*
  • Insulin-Like Growth Factor I / metabolism
  • Neoplasms / drug therapy
  • Receptor, IGF Type 1 / metabolism

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neutralizing
  • Antineoplastic Agents
  • Immunoglobulins, Intravenous
  • cixutumumab
  • Insulin-Like Growth Factor I
  • ganitumab
  • Receptor, IGF Type 1
  • figitumumab